PE 22-28 is a spadin‑derived heptapeptide studied as a fast‑acting antidepressant via TREK‑1 channel blockade; users cite it for mood improvement and emotional balance (7 reports, all positive) and for depression research as a fast‑acting antidepressant (6 reports, 83.3% positive). The common regimen is 250 µg per day, with reported doses spanning 200 µg to 800 µg; most users do not specify timing or cycling. No FDA‑approved indication exists, so all human use is off‑label or compounded, and occasional reports mention altered sleep or dreams.
Data last updated
Measured on 3 of 6 axes
Evidence shape
According to the provided data, the evidence tier for PE 22‑28 is classified as none, reflecting zero human published studies and a depth headline that records zero registered trials. The breadth headline indicates zero indications mapped, and the quality headline states there are no completed trials, which together show an absence of any human trial activity. Consequently, the lack of any registered or completed trials means that no human efficacy or safety data are available, and the peptide’s effects remain unstudied in clinical settings.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 4 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How PE 22-28 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Community users typically take 200–800 mcg of PE 22‑28 subcutaneously, often around 250 mcg, with a minority reporting daily dosing and the rest not specifying frequency.